Articles from Nuvig Therapeutics, Inc.

Nuvig Therapeutics, Inc., (“Nuvig”) a privately held biotechnology company developing novel immunomodulatory therapeutics for patients with inflammatory autoimmune diseases, today announced the appointment of Celia J.F. Lin, M.D., as Chief Medical Officer. Dr. Lin is a physician-scientist and rheumatologist with nearly 15 years of experience leading clinical development for immunomodulating therapies in autoimmune, inflammatory, and fibrotic diseases across biotechnology and large pharmaceutical organizations.

Nuvig Therapeutics, Inc. (“Nuvig”) a privately held biotechnology company developing novel immunomodulatory therapeutics for patients with inflammatory autoimmune diseases, today announced the appointment of David J. Woodhouse, Ph.D., as Chief Executive Officer and member of the Board of Directors and James Mackay, Ph.D., as Independent Board Chair.

Nuvig Therapeutics, Inc. (“Nuvig”), a privately held biotechnology company developing novel immunomodulatory therapeutics for patients with inflammatory autoimmune diseases, today announced that the first patient has been dosed in its Phase 2 clinical trial evaluating NVG-2089 in individuals with chronic inflammatory demyelinating polyneuropathy (CIDP). The company also announced that it will present results from a Phase 1 study of NVG-2089 in healthy volunteers at the 2025 Peripheral Nerve Society (PNS) Annual Meeting on May 19th in Edinburgh, Scotland.

Nuvig Therapeutics, Inc., (“Nuvig”) a privately held biotechnology company developing novel immunomodulatory therapeutics for patients with inflammatory autoimmune diseases, announced today the closing of a $161 million Series B financing. The financing was co-led by Sanofi Ventures, Blue Owl Healthcare Opportunities (formerly Cowen Healthcare Investments), and Norwest Venture Partners, with participation from new investors, B Capital, Leaps by Bayer, Global BioAccess Fund, LOTTE Holdings, Alexandria Venture Investments, and funds managed by abrdn Inc., and existing shareholders, Novo Holdings A/S, Platanus, Bristol Myers Squibb, Digitalis Ventures, and Mission BioCapital.

Nuvig Therapeutics, Inc. (“Nuvig” or the “Company”), a privately held biotechnology company developing novel immunomodulatory therapeutics for patients with inflammatory autoimmune diseases, today announced the first-in-human dosing of NVG-2089, a proprietary product being developed to treat patients with inflammatory myopathies and severe dermatologic autoimmune disease. Nuvig also announced that the FDA granted fast track designation (FTD) for NVG-2089’s development in bullous pemphigoid.

Nuvig Therapeutics, Inc., a biopharma company developing proprietary recombinant human therapeutics for patients with autoimmune diseases, today announced the appointment of Julie Anne Smith as Chief Executive Officer (CEO) and member of the Board of Directors. Ms. Smith has over 20 years of experience in the life science industry, with a focus on leading private and public biotech companies through development and commercialization of therapeutics for orphan diseases. Pamela Conley, Ph.D., cofounder and founding CEO of Nuvig Therapeutics, will serve as the Company’s Chief Scientific Officer.

Nuvig Therapeutics, Inc., a private biotech company developing novel therapeutics to restore immune homeostasis and treat chronic autoimmune diseases, announced today the appointment of Joanne Quan, M.D., as Chief Medical Officer. Dr. Quan has more than 25 years of experience advancing novel drug candidates in all stages of development, from preclinical compounds to marketed products.

Nuvig Therapeutics, Inc., announced today the launch of the company to develop novel therapeutics that induce mechanisms of immune homeostasis and treat autoimmune diseases without compromising normal immune function. To support this mission, the company has closed a $47 million Series A financing, led by Novo Holdings A/S and Platanus, and joined by Bristol Myers Squibb, Digitalis Ventures, and Mission BioCapital.